FDA 2026 Draft Guidance on Alternatives to Animal Testing

On 18 March 2026, the U.S. Food and Drug Administration (FDA) issued draft guidance that formally invites drug sponsors to submit data from new approach methodologies (NAMs) in place of animal studies, even where those methods have not previously been validated by the agency.

For pharmaceutical R&D teams, the guidance reframes the question from ‘are we permitted to use NAMs?’ to ‘what do we need to demonstrate when we do?’

Image

What Prompted This FDA Guidance?

The March 2026 draft guidance is the latest in a sequence of regulatory actions that reflect a sustained FDA commitment to move away from animal testing.

Starting with the FDA Modernization Act 2.0, enacted in late 2022, the longstanding statutory requirement that new drugs be tested in animals before human trials was removed. That legislative change created the legal space.

The FDA's April 2025 Roadmap to Reducing Animal Testing in Preclinical Safety Studies then set out the operational direction, followed by a December 2025 draft guidance that addressed the reduction of non-human primate testing for certain monoclonal antibodies.

The latest March 2026 draft guidance now provides the general framework that sits across all of these.

Alongside the guidance, the National Institutes of Health (NIH) announced more than $150 million in grants for institutions developing research methods that better simulate human biology. This represents a concurrent investment and structural shift in how the U.S. government funds and governs preclinical research.

Image

What the Draft Guidance Sets Out

The central clarification is this: Validation or qualification of a NAM is not required for it to be used in support of a drug application.

The FDA’s Centre for Drug Evaluation and Research (CDER) is making clear it wants to receive NAM data in appropriate cases and that such data can be more predictive and more ethical than animal data.

Four principles govern how a NAM should be presented in a submission:

1. Define the intended regulatory use (context of use): What decision will the NAM data support? Safety assessment, toxicity profiling, pharmacokinetic modelling?
2. Demonstrate relevance to human biology: The method must show it captures the biological processes relevant to the drug's mechanism and target population, especially regarding potential toxicity.
3. Establish and characterise technical reliability: Data must be reproducible and generated to an appropriate standard of scientific rigour.
4. Confirm fitness for regulatory decision-making: The method must be appropriate for the context. A NAM suited to early toxicity screening may not be sufficient for a pivotal safety assessment.

The guidance is deliberately general. It does not mandate specific technologies or address particular drug classes.

Sponsors uncertain about whether a given NAM meets these criteria are encouraged to engage their FDA review division early.

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

What NAMs Are We Talking About?

NAMs encompass a broad spectrum of methodologies, including:

• Organoids: Three-dimensional multicellular structures derived from stem cells that replicate organ-specific architecture and function
• Organs-on-chips: Microfluidic devices that combine cell cultures with dynamic flow systems to simulate multi-organ pharmacokinetics and toxicity
• In silico computational models: Machine learning and simulation-based tools for predicting ADMET properties and toxicity endpoints
• Two-dimensional and complex in vitro systems: Advanced cell culture platforms including patient-derived primary cells and co-culture models
• Chemical read-across and QSAR: Computational methods that estimate properties of untested compounds based on structural similarity to tested compounds

The guidance covers all of these under a unified framework rather than specifying different requirements for each technology.

This is intentional: The FDA wants flexibility in what sponsors submit, not a prescriptive checklist that inadvertently favours one technology category.

Image

What This Means for R&D Strategy

The most immediate implication is that the bar for submitting NAM data has shifted from ‘already approved by the FDA’ to ‘scientifically defensible for this context.’ That is a meaningful change for teams that have been reluctant to include organoid or computational data in IND packages because the method lacked prior regulatory precedent.

For R&D leaders, this has three practical consequences:

1. Pre-submission engagement is now strategic, not optional. The guidance explicitly encourages sponsors to consult review divisions on NAM use. Teams planning to lead with NAM data should be in early conversations with the FDA, not waiting for formal submission.
2. Invest in reproducibility infrastructure. Reliability of NAM data is one of the four core criteria. Organoid culture variability, assay standardisation, and inter-laboratory reproducibility are now regulatory assets, not just scientific quality issues.
3. Track the MAHA Commission direction. The guidance references the MAHA Commission’s strategy report as a driver for reducing reliance on animal studies that ‘often fail to replicate complex human conditions.’ This political alignment makes further tightening of animal testing requirements more probable.

Limitations of the FDA Draft Guidance

The draft guidance does not signal that animal testing should be done away with. There will likely be a stepwise approach and more flexibility when the drug belongs to a class of products where the molecular target is well characterised.

For novel mechanisms, complex biologics, or first-in-class therapies in understudied indications, animal data will still be expected alongside or in preference to NAMs for some time.

There are also no regulatory incentives (expedited review, priority status) attached to NAM submissions at present. The FDA has said it has no current plans to offer such incentives, relying instead on scientific confidence-building to encourage adoption.

Read The Looming Threat of Geopolitical Risk in Clinical Supply Chains

The Looming Threat of Geopolitical Risk in Clinical Supply Chains

Geopolitical risk is reshaping how clinical supply chains are managed, demanding resilience and foresight. Learn why building supply chain resilience is the key for clinical trial success.

Image

Conclusion: Expect to See NAMs Used More in Drug Development and R&D

The March 2026 draft guidance is the most explicit statement the FDA has made about what sponsors need to demonstrate when using NAMs, and the clearest signal yet that the agency is ready to accept human-relevant data in place of animal data when scientifically justified.

The regulatory pathway for NAMs is not fully formed. The guidance is a framework, not a rulebook, and the specific evidence requirements will continue to be negotiated in pre-submission meetings and shaped by precedent cases.

But the direction is unambiguous: The FDA wants sponsors to start submitting and is not waiting for perfect validation frameworks before it wants to see NAM data. 

Pharmatica tracks the evolving regulatory landscape across drug development, providing pharma leaders with the contextual analysis needed to make informed decisions about where and when to invest in next-generation preclinical platforms.

Pharmatica: Insight. Connection. Impact.

Image